Abstract
Survival of gene therapy vectors in the bloodstream, in the presence of cells and proteins of the immune response, is vital for a variety of therapeutic applications. Complement has previously been shown to be activated by a variety of gene therapy vectors. An inflammatory response in blood has been reported in response to adenovirus, but has yet to be demonstrated with baculovirus vectors (bv). A blood ‘loop’ model was used to study human innate immunity to an AcMNPV bv vector in three healthy volunteers and to assess the effects of two complement inhibitors, Compstatin and C5a receptor antagonist (C5aRA).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
